In this episode of our brand new podcast series, Life Sciences Lab Notes from Bristows, James Johnston and Claire Smith explore the US Biosecure Act and its implications for UK and EU biotech companies.
They unpack common misconceptions about the legislation, explain how restrictions on federal funding and procurement could affect international supply chains, and examine the potential impact on commercial partnerships, investment and exit transactions.
With a focus on practical steps, they discuss how biotech businesses can assess supply chain risks, strengthen contractual protections and plan ahead.
/Passle/5f3d6e345354880e28b1fb63/MediaLibrary/Images/2025-09-29-13-48-10-128-68da8e1af6347a2c4b96de4e.png)
/Passle/5f3d6e345354880e28b1fb63/SearchServiceImages/2026-10-14-10-47-01-769-6acf5da591778041f005d442.jpg)
/Passle/5f3d6e345354880e28b1fb63/MediaLibrary/Images/2026-09-11-10-59-38-715-6aa3df1a181cfb8b954e603a.png)
/Passle/5f3d6e345354880e28b1fb63/SearchServiceImages/2026-10-13-15-35-40-862-6ace4fcca1503fba13b73b0a.jpg)